Pramlintide, as an adjunct to long-acting insulin, led to improved A1C and body weight in patients with type 2 diabetes

被引：0

|

作者：

Lush, Cameron

Strobel, Susan

Zhang, Bei

Frias, Juan

机构：

来源：

DIABETES | 2006年 / 55卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A124 / A124

页数：1

相关论文

共 50 条

[1] Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with type 2 diabetes
Frias, Juan
Bei, Zhang
Darsow, Tamara
[J]. DIABETES, 2006, 55 : A112 - A112
[2] Pramlintide, as an adjunct to premixed insulin, reduced A1C and body weight in patients with type 2 diabetes
Lorenzi, Gayle
Zhang, Bei
Darsow, Tamara
Maier, Holly
Wilhelm, Ken
[J]. DIABETES, 2008, 57 : A585 - A585
[3] Pramlintide, as an adjunct to premixed insulin, reduced HbA1c and body weight in patients with type 2 diabetes
Darsow, T.
Lorenzi, G.
Zhang, B.
Maier, H.
Wilhelm, K.
[J]. DIABETOLOGIA, 2008, 51 : S409 - S409
[4] Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight
Karl, Diane
Philis-Tsimikas, Athena
Darsow, Tamara
Lorenzi, Gayle
Kellmeyer, Terrie
Lutz, Karen
Wang, Yan
Frias, Juan P.
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 (02) : 191 - 199
[5] Pramlintide, as an adjunct to basal insulin, reduced C-reactive protein, improved glycemic control, and led to weight loss in patients with type 2 diabetes
Lush, Cameron
Frias, Juan
Zhang, Bei
Maier, Holly
Kolterman, Orville
[J]. DIABETES, 2007, 56 : A144 - A144
[6] Pramlintide, as an adjunct to insulin therapy, led to improved control of both glycemia and weight in African American and Hispanic patients with type 2 diabetes
Kolterman, O
Maggs, D
Burrell, T
Strobel, S
Brown, D
Weyer, C
[J]. DIABETES, 2003, 52 : A124 - A125
[7] rEffects of Pramlintide on A1C, Weight, and Hypoglycemia in Patients With Type 1 or Type 2 Diabetes: Subgroup Analysis by Duration of Diabetes
Herrmann, Kathrin
Brunell, Steven C.
Shan, Kevin
Chen, Steve
[J]. DIABETES, 2013, 62 : A267 - A267
[8] Real-World A1c and Weight Outcomes with Long-Acting GLP-1 Receptor Agonist Treatment by Insulin Use in Patients with Poorly Controlled Type 2 Diabetes
Ruiz-Negron, Natalia
Wittbrodt, Eric
Ma, Junjie
Unni, Sudhir
Hurd, Jeff
Mcadam-Marx, Carrie
[J]. DIABETES, 2017, 66 : A308 - A308
[9] Mechanism for the differential effect of the long-acting insulin analog detemir on weight in patients with type 1 diabetes
Zachariah, S.
Sheldon, B.
Shojaee-Moradie, E.
Jackson, N.
Backhouse, K.
Johnsen, S.
Umpleby, M.
Russell-Jones, D.
[J]. DIABETOLOGIA, 2010, 53
[10] Mechanism for the Differential Effect of the Long-Acting Insulin Analog Detemir on Weight in Patients with Type 2 Diabetes
Sheldon, Ben
Alsini, Najlaa
Zachariah, Sunil
Shojaee-Moradie, Fariba
Bodinham, Caroline
Robertson, Denise
Bell, Jimmy
Thomas, Louise
Vidal, Hubert
Meugnier, Emmanuelle
Jones, Richard H.
Umpleby, A. M.
Russell-Jones, David
[J]. DIABETES, 2011, 60 : A263 - A264

← 1 2 3 4 5 →